Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-09-05
2006-09-05
Eyler, Yvonne (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C514S013800, C514S018700, C514S824000, C514S866000, C514S909000
Reexamination Certificate
active
07101838
ABSTRACT:
The present invention provides for a method to prevent accelerated atherosclerosis in a subject predisposed thereto which comprises administering to the subject a polypeptide derived from soluble receptor for advanced glycation endproduct in an amount effective to prevent accelerated atherosclerosis in the subject. The present invention also provides for a method to prevent a macrovessel disease in a subject predisposed thereto which comprises administering to the subject a polypeptide derived from soluble receptor for advanced glycation endproduct in an amount effective to prevent macrovessel disease in the subject.
REFERENCES:
patent: 5565344 (1996-10-01), Nanba et al.
patent: 5605885 (1997-02-01), Bernton
patent: 5688653 (1997-11-01), Ulrich et al.
patent: 5864018 (1999-01-01), Morser et al.
patent: WO 97/39121 (1997-10-01), None
patent: WO 97/39125 (1998-10-01), None
Brownlee, M., (1992) Diab. Care 15(12): 1835-1842.
Neeper, M. et al., (1992) J. Biol. Chem. 267: 14988-15004.
Schmidt, A.M. et al., (1992) J. Biol. Chem. 267: 14987-14997.
Schmidt, A.M. et al., (1994) Arterioscl. and Thromb. 14: 1521-1528.
Schmidt, A.M. et al., (1995) Nat. Med. 1: 1002-1004.
Schmidt, A.M. et al., (1994) PNAS (USA) 91:8807-8811.
Wautier, J.L. et al., (1996) J. Clin. Invest. 97: 238-243.
Brett, J. et al. (1993) Survey of the distribution of a newly-characterized receptor for AGEs in tissues. Am. J. Pathol. 143: 1699-1712.
Connolly ES, Winfree CJ, Sterm DM, Solomon RA, Pinsky DJ (1996) Procedural and strain-related variables significantly affect outcome in a murine model of focal cerebral ischemia. Neurosurg. 38:523-532.
Gibbons GH and Dzau VJ (1996) Molecular therapies for vascular diseases. Science. 272:389-693.
Basha, Am. Heart J., Jun. 1995, 131 (6): 1192-202.
Hori et al., (1997) The Receptor for Advanced Glycation Endproducts: Implications for the Development of Diabetic Vascular Disease. Fundam. Clin. Cardiol. In: The Endothelium in Clinical Practice. Chapter 11, pp. 311-329.
Khoury, J., et al. (1994) “Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptor.”J. Biol. Chem., 369:10197-10200.
Kindy, S. Mark and Rader, J. Daniel (1998) “Reduction in Amyloid A Amyloid Formation in Apolipoprotein-E-Deficient Mice,”American Journal of Pathology152: 1387-1395.
Marui, N., et al. (1993) “VCAM-1 gene transcription and expression are regulated through an oxidant-sensitive mechanism in human vascular endothelial cells”J. Clin. Invest., 92:1866-1874.
Nakamura Y. et al. (1993) “Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus.”Am. J. Pathol. 143(6): 1649-1656.
Nakashima Y, Plump A, Raines E, Breslow J, Ross R. (1994) “ApoE-deficient mice develop lesions of all phases of atheroslerosis throughout the arterial tree. ” Arterioscler. Thromb. 141:133-140.
Neeper M. et al. (1992) “Cloning and expression of a cell surface receptor for advanced glycosylation endproducts of proteins.” J. Biol. Chem. 267:14998-15004.
Palinski W. et al. (1995) Immunological evidence for the presence of advanced glycation endproducts in atherosclerotic lesions of euglycemi rabbits. Arterioscl. Thromb. and Vasc. Biol. 15(5):571-582.
Park, L.,et al. (1998) Suppression of accelerated diabetic atherosclerosis by soluble Receptor for AGE (sRAGE). Nature Medicine, 4:1025-1031;
Park, L., et al. (1997). A murine model of accelerated diabetic atherosclerosis: suppression by soluble receptor for advanced glycation endproducts. Circulation Supplement. Abstract 3079;
Ritthaler, et al. (1995) Expression of receptors for advanced glycation end products in peripheral occulsive vascular disease. Am. J. Path 146:688-694;
Schmidt, A.M., et al. (1993) Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J. Clin. Invest. 92:2155-2168;
Schmidt, A.M., et al. (1997) The V-Domain of Receptor for advanced Glycation Endproducts (RAGE) mediates binding of AGEs: a novel target for therapy of diabetes. Circulation Supplement, 96:194:1-37;
Schmidt, A.M., et al. (1994) Cellular receptors for advanced glycation end products.Arterioscler. Thromb, 14:1521-1528;
Schmidt, A.M., et al.(1995) The Dark Side of Glucose (News and Views). Nature Medicine, 1:1002-1004;
Schmidt, A-M, et al.(1994) Receptor for advanced glycation endproducts (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc. Natl. Acad. Sci. (USA), 91:8807-8811;
Schmidt, A-M, Yan S-D, Wautier J-L, Stern DM; Activation of RAGE: a mechanism for chronic dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84:489-497;
Vlassara, H., et al. (1995) Identification of Galectin-3 as a high affinity binding protein for advanced Glycation Endproducts (AGE): a new member of the AGE-Receptor complex. Molecular Medicine, 1:634-646;
Vlassara,H., et al. (1994). Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab. invest. 70:138-151;
Wautier, J.L., et al. (1996) Receptor-mediated endothelial dysfunction in diabetic vasculopathy: Srage blocks hypermeability in diabetic rats .J. Clin. Invest., 97(1): 238-243.
Wautier, J.L., et al. (1996). Interaction of diabetic erthrocytes bearing advanced glycation endproducts with the endothelial receptor AGE induces generation of reactive oxygen intermediates and cellular dystfunction. Circulation supplement 94 (8):4139;
Yan, S-D., et al. (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation endproducts with their receptors/binding proteins. J.Biol.Chem.,269:9889-9897.
Schmidt Ann Marie
Stern David
Cooper & Dunham LLP
Eyler Yvonne
Lazar-Wesley Eliane
The Trustees of Columbia University in the City of New York
White, Esq. John P.
LandOfFree
Method to prevent accelerated atherosclerosis using (sRAGE)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method to prevent accelerated atherosclerosis using (sRAGE)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method to prevent accelerated atherosclerosis using (sRAGE)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3592811